مباشر

LabiotechTIL therapies: the impact on cancer research FierceBiotechAstraZeneca pens agentic AI licensing deal with Owkin 10x Genomics BlogWhy 10x Genomics (TXG) Stock Is Down Today - Yahoo Finance 10x Genomics Blog10x Genomics, Harvard Target Element’s Multiomics Platform in Patent Lawsuit - Genetic Engineering and Biotechnology News 10x Genomics News10x Genomics, Harvard Target Element’s Multiomics Platform in Patent Lawsuit - Genetic Engineering and Biotechnology News Science Daily BiotechA rare cancer-fighting plant compound has been decoded Eli LillyEli Lilly Clinical Trial Shows Its Obesity Drugs Can Cause Weight Loss And Help Maintain It - Stocktwits eLifeExamining the role of lipids in hearing Endpoints NewsLilly points to low-dose Zepbound and Foundayo as weight loss maintenance options IlluminaThe Bull Case For Illumina (ILMN) Could Change Following Upgraded 2026 Outlook And Major Buyback - Learn Why - simplywall.st Siemens HealthineersA Look At Siemens Healthineers (XTRA:SHL) Valuation After New HKSH Photon‑Counting CT Partnership - simplywall.st LabCorpLabcorp and Epic Expand Collaboration for Lab Test Ordering - Clinical Lab Products

FierceBiotech ١٣ مايو ٢٠٢٦

AstraZeneca pens agentic AI licensing deal with Owkin

AstraZeneca is the latest Big Pharma company looking to tap into agentic artificial intelligence (AI), inking a three-year licensing deal with Owkin to leverage...

AstraZeneca is the latest Big Pharma company looking to tap into agentic artificial intelligence (AI), inking a three-year licensing deal with Owkin to leverage its autonomous “AI Scientist” platform.